Delcath Systems (DCTH)
NASDAQ:DCTH
Want to see DCTH full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
0.07Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a balanced mix of positive commercial and clinical momentum (record new patient starts, robust volume growth, encouraging CHOPIN data driving adoption, solid revenue growth and strong cash balance) alongside meaningful near-term operational and financial headwinds (slower-than-expected site activations and trial enrollment, higher R&D and SG&A spend, a quarter-over-quarter decline in adjusted EBITDA and a small net loss, plus European reimbursement constraints and seasonality risks). Management remains optimistic about hitting at least $100M in revenue for 2026 and returning to positive adjusted EBITDA for the year, but several execution and enrollment risks temper the outlook.Company Guidance
Top-Line Revenue Growth
Total revenue for Q1 2026 was $25.0M vs $19.8M in Q1 2025, an increase of approximately 26.3% year-over-year. HEPZATO KIT revenue was $23.3M and CHEMOSAT revenue was $1.7M.
Volume Momentum and New Patient Starts
Company reported record new patient starts in Q1 and new patient starts per site tracked at ~0.7 new patients per site per month (at or slightly higher than Q1 2025). Management cited 36% year-over-year volume growth for the quarter (per press release) and mid-20% quarter-over-quarter volume growth vs Q4 2025.
Commercial Footprint Expansion
Nearly completed U.S. commercial expansion into 9 regions; expanded MSL team fully trained and deployed; 29 REMS-certified sites as of the call and active discussions with over 50 potential centers (38 of which have had team members participate in precepting).
CHOPIN Clinical Evidence Driving Adoption
CHOPIN results (published in Lancet Oncology) showed response rates improving from ~40% with HEPZATO alone to ~76% with HEPZATO plus immunotherapy, including some complete responses and survival separation at 1 and 2 years. Management reported anecdotal physician adoption and that CHOPIN is influencing treatment patterns at multiple centers.
Guidance and Profitability Outlook
Company reiterated guidance of at least $100M total revenue for 2026 (reflecting 20% growth in HEPZATO kit volume over 2025), maintained gross margin guidance of 85%–87%, and expects to report positive adjusted EBITDA for the remainder of the year.
Clinical Program Progress
Metastatic colorectal cancer program has 13 sites active for screening and is on track to activate nearly all targeted 26 trial sites by year-end 2026; metastatic breast cancer program has 4 sites ready to screen and is targeting 15 sites by late 2026. Interim CRC results anticipated in late 2027.
Cash Position and Balance Sheet
Ended Q1 with $89.3M in cash and investments and no debt; cash provided by operations was $0.9M in the quarter. Company also executed share repurchases (~300,000 shares for ~$3M in Q1; $9M repurchased to date under $25M program).
Operational Initiatives to Mitigate Seasonality
Management implemented incentives to train second treatment teams at centers to reduce seasonal capacity disruptions and is building referral networks and multi-source identification strategies to accelerate patient referrals.
DCTH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DCTH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $11.26 | $11.24 | -0.18% |
Feb 26, 2026 | $10.21 | $9.00 | -11.85% |
Nov 04, 2025 | $9.52 | $9.08 | -4.62% |
Aug 06, 2025 | $10.52 | $10.64 | +1.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Delcath Systems (DCTH) report earnings?
Delcath Systems (DCTH) is schdueled to report earning on Aug 10, 2026, TBA (Confirmed).
What is Delcath Systems (DCTH) earnings time?
Delcath Systems (DCTH) earnings time is at Aug 10, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DCTH EPS forecast?
DCTH EPS forecast for the fiscal quarter 2026 (Q2) is -0.09.